IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 6, 2010, Pages 724-733

  Alici, Evren ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G4; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ARTICLE; BURKITT LYMPHOMA; CELL ACTIVITY; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID; MULTIPLE MYELOMA; PROTEIN BINDING; RECEPTORS, KIR; RECEPTORS, NATURAL KILLER CELL;

EID: 79952939196     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Innate Pharma and Novo Nordisk A/S sign licensing deal which opens new avenue in cancer immunotherapy. Innate Pharma SA PrEss rElEasE 2003 December 09
2. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP et al Blood 2001 98 1 210-216
3. Tumor-induced immune dysfunction. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M Cancer Immunology Immunotherapy 1999 48 7 353-362 (Pubitemid 29461387) (Pubitemid 29461387)
4. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease. Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R Int J Cancer 1995 61 6 765-772
5. Pilot study of low dose melphalan and bortezomib for treatment of acute myelogenous leukemia and high-risk myelodysplastic syndromes. Bubis JA, Ely P, Meehan KR, Stearns D, Schaal AD, Kimtis EA, Lowrey C, Bengtson EM, Hill J, Gautier M Blood 2005 106 11 Abs 4633
6. Innate Pharma and Novo Nordisk announce strategic partnership to research and develop drugs targeting natural killer cells. Novo Nordisk A/S, Innate Pharma SA Press Release 2006 April 06
7. Innate Pharma company web site and pipeline. Innate Pharma SA Company World Wide Web Site 2007 January 09
8. Innate Pharma announces the frst human dose for IPH 2101 (NN 1975). Innate Pharma SA Press Release 2007 February 08
9. Innate Pharma announces the start of a new clinical trial with IPH 2101 (NN 1975), the frst under U.S.IND. Innate Pharma SA PrEss rElEasE 2007 June 25
10. Product update: New product-Revlimid. Celgene Corp MIMs (lONDON) 2007 August 8
11. A randomized phase 3 study of tipifarnib compared to best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 years or older. Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein J, Bourdessoule D, Masszi T, Ossenkoppele G, Alexeeva JA, Beutel G, Park YC, De Porre P, Howes AJ Blood 2007 110 11 Abs 439
12. Anti-KIR (1-7F9): A fully human monoclonal antibody (mAb) that blocks KIR2DL1,-2 and-3, promoting natural killer (NK) cell-mediated lysis of tumor cells in vitro and in vivo. Wagtmann N, Andre P, Zahn S, Spee P, Anfossi N, Gauthier L, Blaser BW, Caligiuri MA, Capanni M, Ruggeri L, Velardi A et al Blood 2007 110 11 Abs 582
13. Innate Pharma and Novo Nordisk A/S Partnership Refocused On The Infammatory Feld. Novo Nordisk A/S Press Release 2008 January 31
14. Annual general meeting resolutions and update on the divestment process by Novo Nordisk A/S of its rights to IPH 2101. Innate Pharma SA Press Release 2008 July 07
15. Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results. Benson DM, Romagne F, Squiban P, Wagtmann N, Farag S, Mita A, Hofmeister C, Smith M, Bakan C, Caligiuri M J Clin Oncol 2009 27 15S Abs 3032
16. A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML). Vey N, Bourhis J, Dombret H, Bordessoule D, Prebet T, Charbonnier A, Squiban P, Damholt B, Blaise D, Olive D J Clin Oncol 2009 27 15S Abs 3015
17. Start of the frst phase II clinical trial with monoclonal antibody IPH 2101 supported by a new 2.9 millions euros fnancing from OSEO. Innate Pharma SA Press Release 2009 August 27
18. Vion Pharmaceuticals Pipeline (as of January 2009). Vion Pharmaceuticals Inc Company World Wide Web Site 2009 January 31
19. Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of Revlimid combined with anti-KIR antibody IPH 2101 in patients with multiple myeloma. Innate Pharma SA Press Release 2009 November 18
20. Novel monoclonal antibody enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Interim phase 1 trial results. Benson D, Hofmeister CC, Padmanabhan S, Abonour R, Suvannasankha A, Mita A, Squiban P, Smith MK, Bakan CE, Marzetto M, Andre P et al Blood 2009 114 22 Abs 2880
21. A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML): Clinical and immunological effects of a single dose followed by repeated dosing. Vey N, Bourhis J-H, Dombret H, Bordessoule D, Prebet T, Charbonnier A, de Botton S, Boissel N, d'Arnoux C, Romagne F, Andre P et al Blood 2009 114 22 Abs 632
22. A phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients > 60 years old. Vij R, Nelson A, Uy GL, Abboud C, Westervelt P, Cashen AF, Stockerl-Goldstein K, Trinkhaus KM, DiPersio JF, Fehniger TA Blood 2009 114 22 Abs 842
23. IPH2101, a novel anti-inhibitory KIR monoclonal antibody, and lenalidomide combine to enhance the natural killer (NK) cell versus multiple myeloma (MM) effect. Benson D, Bakan CE, Zhang SH, Alghothani L, Liang J, Hofmeister C, Srivastava S, Smith MK, Greenfeld CN, Andre P, Squiban P et al Blood 2009 114 22 Abs 3870
24. A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma. Benson DM, Padmanabhan S, Hofmeister CC, Bakan CE, Abonour R, Suvannasankha A, Efebera YA, Squiban PJ, Caligiuri MA, Farag S J Clin Oncol 2010 28 15S Abs 8139
25. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DMJ, Blaser BW, Della CM et al Blood 2009 114 13 2667-2677
26. Nk cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients. Johansson SE, Hejdeman B, Hinkula J, Johansson MH, Romagne F, Wahren B, Wagtmann NR, Karre K Berg L Clin Immunol 2010 134 2 158-168
27. Enhanced NK cell mediated cytotoxicity against multiple myeloma (MM) cells by the combination of anti-KIR (1-7F9) monoclonal antibody (mAb) and lenalidomide. Zhang S, Liang J, Chen L, Homsi Y, Wang X, Feng H, Srivastava S, Farag SS Proc Am Assoc Cancer Res 2009 50 Abs 3245
28. Enhancing natural killer (NK) cell mediated killing of non-Hodgkin's lymphoma. Srivastava S, Feng H, Zhang S, Liang J, Squiban P, Farag S Blood 2009 114 22 Abs 2706
29. Characterization of early natural killer cell reconstitution following autologous transplantation in multiple myeloma. Benson D, Bakan CE, Alghothani L, Hofmeister CC, Efebera YA, Smith MK, Greenfeld CN, Andre P, Squiban P, Romagne F, Caligiuri MA et al Blood 2009 114 22 Abs 4641
30. Dysfunctional T regulatory cells in multiple myeloma. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC et al Blood 2006 107 1 301-304 (Pubitemid 43053555) (Pubitemid 43053555)
31. In vivo peripheral expansion of na?ve CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA, Classen S, Schultze JL Blood 2006 107 10 3940-3949 (Pubitemid 43726800) (Pubitemid 43726800)
32. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I, Donk NW Verdonck LF J Clin Oncol 2000 18 16 3031-3037 (Pubitemid 30648798) (Pubitemid 30648798)
33. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, Facon T, Granena A, Gore M, Gratwohl A, Löwenberg B et al N Engl J Med 1991 325 18 1267-1273
34. Treatment of multiple myeloma: An emphasis on new developments. Kyle R, Vincent RS Ann Med 2006 38 2 111-115
35. Progress in hematopoietic stem cell transplantation in multiple myeloma. Gahrton G CUrr OPIN HEMaTOl 2005 12 6 463-470 (Pubitemid 41546477) (Pubitemid 41546477)
36. Outcomes for reduced-intensity allogeneic trans-plantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, Juliusson G, Ahlberg L, Nagler A, Shimoni A, Sureda A et al Blood 2005 105 11 4532-4539 (Pubitemid 40720805) (Pubitemid 40720805)
37. Natural killer cell activity and cytokine production as prognostic factors in adult acute Leukemia. Tajima F, Kawatani T, Endo A, Kawasaki H Leukemia 1996 10 3 478-482 (Pubitemid 26128788) (Pubitemid 26128788)
38. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid Leukemia. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A Blood 2002 99 10 3661-3667 (Pubitemid 34534536) (Pubitemid 34534536)
39. Variable expression of CD3-ς and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Buggins AG, Hirst WJ, Pagliuca A, Mufti GJ Br J Haematol 1998 100 4 784-792 (Pubitemid 28126116) (Pubitemid 28126116)
40. IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. Frassanito MA, Silvestris F, Cafforio P, Silvestris N, Dammacco F Int J Clin Lab Res 1997 27 1 48-54
41. Natural killer activity and antibody-dependent cell-mediated cytotoxicity in multiple myeloma. Matsuzaki H, Kagimoto T, Oda T, Kawano F, Takatsuki K Jpn J Clin Oncol 1985 15 4 611-617
42. Natural killer cell activity in patients with multiple myeloma. Ogmundsdottir HM Cancer Detect Prev 1988 12 1-6 133-143
43. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Fauriat C, Mallet F, Olive D, Costello RT Leukemia 2006 20 4 732-733
44. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, Morgan GJ et al Cancer Res 2007 67 18 8444-8449 (Pubitemid 47437416) (Pubitemid 47437416)
45. Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. Nielsen H, Nielsen HJ, Tvede N, Klarlund K, Mansa B, Moesgaard F, Drivsholm A Apmis 1991 99 4 340-346
46. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma. Alici E, Bjorkstrand B, Treschow A, Aints A, Smith CI, Gahrton G, Dilber MS Cancer Gene Ther 2007 14 3 227-232
47. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF et al Science 2002 295 5562 2097-2100 (Pubitemid 34229476) (Pubitemid 34229476)
48. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function-implications for the adoptive immunoTherapy of leukaemia. Orleans-Lindsay JK, Barber LD, Prentice HG, Lowdell MW Clin Exp Immunol 2001 126 3 403-411 (Pubitemid 34008710) (Pubitemid 34008710)
49. Defcient expression of NCR in NK cells from acute myeloid Leukemia: Evolution during Leukemia treatment and impact of Leukemia cells in NCRdull phenotype induction. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT Blood 2007 109 1323-330
50. Natural killer cell receptor signaling. Lanier LL Curr Opin Immunol 2003 15 3 308-314 (Pubitemid 36645107) (Pubitemid 36645107)
51. Exploitation of alloreactive NK cells in adoptive immunoTherapy of Cancer. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A Curr Opin Immunol 2005 17 2 211-217 (Pubitemid 40343110) (Pubitemid 40343110)
52. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with Cancer. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ et al Blood 2005 105 8 3051-3057
53. Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Ruggeri L, Mancusi A, Burchielli E, Aversa F, Martelli MF, Velardi A Cytotherapy 2006 8 6 554-558 (Pubitemid 44869855) (Pubitemid 44869855)
54. Enhanced cytotoxicity of alloGeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JPJ, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW Blood 2004 104 1 170-177 (Pubitemid 38879854) (Pubitemid 38879854)
55. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: Immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Nguyen S, Dhedin N, Vernant JP, Kuentz M, Al Jijakli A, Rouas-Freiss N, Carosella ED, Boudifa A, Debre P, Vieillard V Blood 2005 105 10 4135-4142 (Pubitemid 40656166) (Pubitemid 40656166)
56. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Schulze A, Schirutschke H, Oelschlagel U, Schmitz M, Fussel M, Wassmuth R, Ehninger G, Bornhauser M, Platzbecker U Exp Hematol 2008 36 4 378-389
57. Ex vivo induction of multiple myeloma-specifc cytotoxic T lymphocytes. Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D, Anderson KC Blood 2003 102 4 1435-1442 (Pubitemid 36988054) (Pubitemid 36988054)
58. Recurrent pneumonia in multiple myeloma and some observations on immunologic response. Zinneman HH, Hall WH aNN INTErN MED 1954 41 6 1152-1163
59. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, Ho PJ, Hart D, Joshua D Blood 2001 98 10 2992-2998
60. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L aNNU rEV IMMUNOl 2001 19 197-223 (Pubitemid 32368034) (Pubitemid 32368034)
61. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Bryceson YT, March ME, Ljunggren HG, Long EO Blood 2006 107 1 159-166 (Pubitemid 43053538) (Pubitemid 43053538)
62. Negative regulation of immunoreceptor signaling. Veillette A, Latour S, Davidson D Annu Rev Immunol 2002 20 669-707 (Pubitemid 34293437) (Pubitemid 34293437)
63. Negative signaling by inhibitory receptors: The NK cell paradigm. Long EO Immunol Rev 2008 224 70-84
64. Natural killer and γ δ T cells in haematological malignancies: Enhancing the immune effectors. Rey J, Veuillen C, Vey N, Bouabdallah R, Olive D Trends Mol Med 2009 15 6 275-284
65. Harnessing the immune response to treat Cancer. Steer HJ, Lake RA, Nowak AK, Robinson BW Oncology 2010 September 20 Epub ahead of print
66. Regulation of the natural killer cell receptor repertoire. Raulet DH, Vance RE, McMahon CW Annu Rev Immunol 2001 19 291-330 (Pubitemid 32368038) (Pubitemid 32368038)
67. Functionally and structurally distinct NK cell receptor repertoires in the peripheral Blood of two human donors. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, Phillips JH, Lanier LL, Parham P Immunity 1997 7 6 739-751 (Pubitemid 28064888) (Pubitemid 28064888)
68. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specifc for self-MHC molecules. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH Blood 2005 105 11 4416-4423 (Pubitemid 40720789) (Pubitemid 40720789)
69. A subpopulation of human peripheral Blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, Bergemann TL, McQueen KL, Guethlein LA, Parham P, Miller JS Blood 2007 110 2 578-586 (Pubitemid 47105396) (Pubitemid 47105396)
70. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence. Petrie EJ, Clements CS, Lin J, Sullivan LC, Johnson D, Huyton T, Heroux A, Hoare HL, Beddoe T, Reid HH, Wilce MC et al J Exp Med 2008 205 3 725-735 (Pubitemid 351439316) (Pubitemid 351439316)
71. Current and emerging Therapies for acute myeloid Leukemia. Robak T, Wierbowska A ClIN Ther 2009 31 2349-2370
72. Drug Therapy: Multiple myeloma. Kyle RA, Rajkumar SV N Engl J Med 2004 351 18 1860-1873
73. Progress in alloGeneic transplantation for multiple myeloma. Gahrton G Eur J Haematol 2010 85 4 279-289
74. Acute myeloid leukaemia. Estey E, Dohner H Lancet 2006 368 9550 1894-1907 (Pubitemid 44794525) (Pubitemid 44794525)
75. SEER Stat Fact Sheets: Myeloma. National Cancer Institute WEB sITE 2010 October 29
76. SEER Stat Fact Sheets: Acute Myeloid Leukemia. National Cancer Institute WEB sITE 2010 October 29
77. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemoTherapy in induction and consolidation in younger patients with acute myeloid Leukemia. Kell WJ, Burnett AK, Chopra R, Yin JAL, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan DW Blood 2003 102 13 4277-4283 (Pubitemid 37494084) (Pubitemid 37494084)
78. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, Childs R Cancer Res 2006 66 14 7317-7325 (Pubitemid 44197714) (Pubitemid 44197714)
79. Protection from lysis by natural killer cells of group 1 and 2 specifcity is mediated by Residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. Mandelboim O, Reyburn HT, ValesGomez M, Pazmany L, Colonna M, Borsellino G, Strominger JL J EXP MED 1996 184 3 913-922